Sujal A. Shah
Net Worth

Last updated:

What is Sujal A. Shah net worth?

The estimated net worth of Mr. Sujal A. Shah is at least $12,301,280 as of 13 Mar 2024. He has earned $3,275,010 from insider trading and has received compensation worth at least $9,026,270 in CymaBay Therapeutics, Inc..

What is the salary of Sujal A. Shah?

Mr. Sujal A. Shah salary is $820,570 per year as Pres, Chief Executive Officer & Director in CymaBay Therapeutics, Inc..

How old is Sujal A. Shah?

Mr. Sujal A. Shah is 52 years old, born in 1973.

What stocks does Sujal A. Shah currently own?

As insider, Mr. Sujal A. Shah owns shares in one company:

Company Title Shares Price per share Total value
CymaBay Therapeutics, Inc. (CBAY) Pres, Chief Executive Officer & Director 171,301 $0 $0

What does CymaBay Therapeutics, Inc. do?

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY logo
CBAY
CymaBay Therapeutics, Inc.

Sujal A. Shah insider trading

CymaBay Therapeutics, Inc.

Mr. Sujal A. Shah has made 3 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 64,865 units of CBAY stock on 11 Dec 2023. As of 13 Mar 2024 he still owns at least 171,301 units of CBAY stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 1 $2.94 $3
Option
Common Stock 52,084 $1.72 $89,584
Option
Common Stock 14,625 $1.06 $15,503
Option
Common Stock 2,288 $5.78 $13,225
Option
Common Stock 22,076 $4.05 $89,408
Option
Common Stock 14,372 $8.43 $121,156
Option
Common Stock 3,125 $11.69 $36,531
Option
Common Stock 18,899 $9.21 $174,060
Sale
Common Stock 64,865 $20.4 $1,323,116
Option
Stock Appreciation Right 12,973 $5 $64,865
Option
Common Stock 890 $5 $4,450
Option
Common Stock 63,975 $5 $319,875
Option
Employee Stock Option (right to buy) 20,856 $5 $104,280
Option
Employee Stock Option (right to buy) 20,855 $5 $104,275
Option
Stock Appreciation Right 12,972 $5 $64,860
Option
Common Stock 44,008 $5 $220,040
Sale
Common Stock 64,863 $15.89 $1,030,608
Option
Employee Stock Option (right to buy) 31,036 $5 $155,180
Option
Common Stock 20,855 $5 $104,275
Option
Common Stock 64,861 $5 $324,305
Option
Employee Stock Option (right to buy) 31,034 $5 $155,170
Option
Employee Stock Option (right to buy) 20,855 $5 $104,275
Option
Stock Appreciation Right 12,972 $5 $64,860
Sale
Common Stock 64,861 $14.2 $921,286
Purchase
Common Stock 51,301 $1.95 $100,037
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 3,100 N/A N/A
Purchase
Common Stock 1,900 N/A N/A
Purchase
Common Stock 10,000 $6.54 $65,400
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 5,000 $10.9 $54,500
Purchase
Common Stock 5,000 $10.65 $53,250
Purchase
Common Stock 10,000 $7.31 $73,140
Purchase
Common Stock 33,000 $1.39 $45,870
Purchase
Common Stock 22,000 $1.39 $30,580
Purchase
Common Stock 10,000 $3.4 $34,000
Purchase
Common Stock 10,000 $7.44 $74,400

CymaBay Therapeutics key executives

CymaBay Therapeutics, Inc. executives and other stock owners filed with the SEC: